tbuckley/cabot-search huggingface dataset:
Influence of Pretreatment with Amphotericin B on Treatement-Related Mortality (TRM) Following Allogeneic Stem Cell Transplantations.
Authors: Rudolf Trenschel, Markus Ditschkowski, Nina K. Steckel, Michal Hlinka, Ahmet Elmaagacli, Helmut Ottinger, Micheal Flasshove, Dietrich W. Beelen
Journal: Blood (2004)
Action valence and affective perception
Authors: Walter Gerbino, Carlo Fantoni
Journal: Behavioral and Brain Sciences (2016)

Respecting all constraints proposed by Firestone & Scholl (F&S), we have shown that perceived facial expressions of emotion depend on the congruency between bodily action (comfort/discomfort) and target emotion (happiness/anger) valence. Our studies challenge any bold claim against penetrability of perception and suggest that perceptual theory can benefit from demonstrations of how - under controlled circumstances - observer's states can mold expressive qualities.
A multicenter, open-label, randomized phase II trial of adenovirus-mediated endostatin gene therapy in combination with paclitaxel and cisplatin chemotherapy in advanced head and neck carcinoma: Preliminary results.
Authors: W. Huang, J. Wu, X. Lin, S. Li, R. Liu, W. Hu, Y. Xia, L. Zhang, W. Jiang, Z. Guan
Journal: Journal of Clinical Oncology (2010)

e16005 Background: E10A is an adenovirus containing human endostatin gene (Ad-rhE). The phase I clinical trial of E10A revealed that weekly intratumoral injection of up to 1 × 1012 VP of E10A to patients with solid tumor is a feasible and well-tolerated procedure that exerts mild antitumor effects. In this trial, we aimed to evaluate the safety and efficacy of E10A combined with paclitaxel/cisplatin chemotherapy in advanced head and neck carcinoma (ClinicalTrials.gov identifier: NCT00634595). Methods: Patients treated with chemotherapy alone were given paclitaxel (160mg/m2 on d1) and cisplatin (25mg/m2 on d1, d2 and d3) every 21 days. Patients in combination group received two intratumral injections of E10A on days 1 and 8, combined with paclitaxel (160mg/m2 on d3) and cisplatin (25mg/m2 on d3, d4 and d5), and then every 21 days as long as no PD or untolerable toxicity occurred. The primary efficacy criterion was response rate (CR/PR) determined in cycle 2 to cycle 4. Patients were assessed for toxicity and viral shedding, and antitumor response was evaluated by imaging techniques and tumor biopsy. Results: As of December 2009, evaluable population included sixty-eight subjects. In combination group, 1/34 (2.9%) had CR and 17/34 (50%) had PR. For patients received chemotherapy alone, 1/34 (2.9%) had CR and 7/34 (20.6%) had PR. The most frequent adverse events associated with E10A were fever and local reaction of injection site, primarily grades 1 and 2. Conclusions: Intratumoral injection of E10A is feasible and well tolerated and shows encouraging antitumor effects. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, GlaxoSmithKline AstraZeneca, Bayer, Novartis, sanofi-aventis
NIMG-01ADVANCED MR PERFUSION AND DIFFUSION MEASURES DISTINGUISH BETWEEN GLIOMA SUBTYPES
Authors: Mona Al-Gizawiy, Melissa Prah, Wade Mueller, Kathleen Schmainda
Journal: Neuro-Oncology (2015)

BACKGROUND: Advanced MR imaging provides invaluable information on brain tumor biology and behavior, making it an important complement to standard histopathology. In light of mounting molecular evidence against the existence of true mixed gliomas, we present the use of relative cerebral blood volume (rCBV) to classify gliomas as a function of glioma tumor type and grade. METHODS: Histopathological findings of 145 tissue specimens from 42 consented adult patients were studied. Histopathological diagnosis for each tissue specimen was obtained from the neurosurgical pathology report and according to the WHO brain tumor grading system. Preoperative (≤ 3 months) DSC-MRI and T1 + C images were co-registered to MR Imaging uploaded for surgical navigation. Guided by intraoperative screenshots from a StealthStation® S7™ surgical navigation unit, a 6-mm spherical region of interest (ROI) was drawn manually for each distinct tissue sampling site. Median Apparent Diffusion Coefficient (ADC) and standardized leakage-corrected rCBV values (sRCBV) were determined using the same ROIs. Only positive non-zero values were included in the analysis. Statistical sample independence for both sRCBV and ADC was confirmed before conducting statistical analyses. RESULTS: The sRCBV measures for grade 2 gliomas were comparable across type, yet the ADC values demonstrate a significant distinction of astrocytomas from oligodendrogliomas (p < 0.01) and mixed oligoastrocytomas (p < 0.001). Grade 3 astrocytomas also exhibited significantly different sRCBV and ADC values from oligodendrogliomas (p < 0.05) and oligoastrocytomas (p < 0.001). Similarly, the sRCBV and ADC values were significantly different between pure grade 4 astrocytomas (GBM) and GBMs with oligodendroglial component (p < 0.001). No significant differences were noted between oligodendrogliomas and oligoastrocytomas. CONCLUSION: Significant differences in perfusion and diffusion measures highlight the biologically distinct character of astrocytomas and oligodendrogliomas. Mixed gliomas share more similarities with oligodendrogliomas than with astrocytomas on advanced MR imaging, supporting the hypothesis that mixed gliomas may not represent a separate glioma subtype.
Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis
Authors: David C Knox, Peter L Anderson, P Richard Harrigan, Darrell H S Tan
Journal: New England Journal of Medicine (2017)

The authors reply: Gerhard raises an important question.Iron overload and advanced liver disease have been associated with V. vulnificus infection, specifically with septicemia, 1 and experimental models support enhanced vibrio replication in iron-rich environments. 2Isolated cases of hemochromatosis diagnosis after V. vulnificus wound infection have been reported. 3However, we are aware of no epidemiologic studies of V. vulnificus wound infection and iron overload.Given the recognized association of V. vulnificus infection with liver disease, which is often coincident with iron overload, we agree that it is prudent for patients with liver disease or iron overload to take precautions with shellfish exposure.In the absence of other indicators of hemochromatosis, the usefulness of screening patients with V. vulnificus infection for this diagnosis remains uncertain.In our patient, iron studies revealed a depressed serum iron level of 16 μg per deciliter (normal range, 40 to 159) and a calculated transferrin saturation of 7% (normal range, 25 to 45).These findings were consistent with hypoferremia induced by acute inflammation, 4 and the values subsequently normalized.
Hypermethylation of DNA and Increased Expression of DNMT1 May Represent a Protective Mechanism from Oxidative Stress and DNA Damage in MDS.
Authors: Anna M. Jankowska, Lukasz P. Gondek, Hadrian Szpurka, Zachary P. Nearman, Ramon Tiu, Jaroslaw P. Maciejewski
Journal: Blood (2007)
The effect of epithelial–mesenchymal transition induced by snail transfection in esophageal squamous cancer cell lines.
Authors: C. Tzao, M. Wu, B. Chen
Journal: Journal of Clinical Oncology (2011)

e14505 Background: Cancer stem cell (CSC) has been shown to be an important player in tumorigenesis and tumor progression. Epithelial-mesenchymal transition (EMT) is closely linked with processes in embryogenesis and it has been shown that EMT generates properties of stem cell-like cells in human cancer. Methods: A lentivirus system was used to overexpress human Snail, an EMT regulator, by transfection with a plasmid (pLV-EF1a-hSnail-Hyg), into KYSE 170 and KYSE 510 esophageal squamous cell carcinoma (ESCC) cell lines (kindly provided by Dr. Yutaka Shimada). Immunoblotting was used to determine expression of EMT associated markers (i.e., vimentin, E-cadherin, fibronectin and N-cadherin). Migration and invasion assays were conducted in Snail-transfected cells with a comparison to their vector controls. Cytotoxicity (MTT) and cell proliferation assay were used to determine cell growth properties. In addition, sphere formation assay and flow cytometry (FCM) were employed to characterize in part stem cell properties while examining expression of stemness gene by real-time polymerase chain reaction (PCR). Results: After Snail transfection, mesenchymal markers, vimentin and N-cadherin increased, whereas epithelial marker E-cadherin decreased.Snail-transfected ESCC cells presented a significant increase in RNA expression of stemness genes (i.e., Nanog, Oct4, ABCG2 and Sox2) and in sphere formation. Invasion ability increased after Snail-transfection in ESCC cell lines with a decreased chemosensitivity to cisplatin, taxol, 5’ FU and suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor. Conclusions: Our results demonstrated that Snail induced EMT generated properties of CSC in ESCC cell lines.
Efficacy of Imatinib Mesylate in the Treatment of Refractory Sclerodermatous Chronic Graft-Versus-Host Disease.
Authors: Ibrahim YakoubAgha, Leonardo Magro, Benoit Catteau, Christophe Willekens, Valerie Coiteux, Benedicte Bruno, Louis Terriou, Jean-Pierre Jouet
Journal: Blood (2008)
Gene expression profiling of oral preneoplastic lesions (OPL) from a prospective prevention trial.
Authors: P. Saintigny, L. Zhang, A. K. El-Naggar, V. Papadimitrakopoulou, L. Feng, J. Lee, E. S. Kim, W. K. Hong, S. M. Lippman, L. Mao
Journal: Journal of Clinical Oncology (2010)

5521 Background: Some patients with OPL develop oral cancer (OC). We hypothesized that gene expression profiles in OPL marked the risk of OC development. We tested the hypothesis in the largest patient population enrolled in a long-term prospective, randomized prevention trial conducted in OPL patients, and the first trial that included long-term OC free survival (OCFS) as a pre-specified secondary endpoint (J Clin Oncol 2009;27:599). Methods: Gene expression profile was assessed using Affymetrix HG 1.0 ST platform in 86/162 patients included in a clinical trial comparing retinyl palmitate alone or plus beta-carotene with low dose 13-cis retinoic acid in OC development. Among the 86 patients, 35 developed OC and 51 remained cancer-free (median followup for censored data: 6 years). A boosting approach was used to develop a predictive model in combination with clinical and histological covariates associated with OC development in our previous studies (age, histology at baseline, podoplanin and deltaNp63 protein expression). Results: We identified 2,182 genes that were significantly associated with a risk of developing OC (p-value<0.01, Cox proportional hazard model). We developed an OC index using the 2,182 genes, which can be applied to any microarray gene expression dataset. We found that the OC risk index was able to discriminate head and neck squamous cell carcinoma from normal mucosa in 8 publicly available and independent datasets; morevover, the index was strongly correlated with a signature developped in normal bronchial epithelial cells from smokers to predict the presence of lung cancer (Spira et al. Nat Med 2007). Using age, histology at baseline, podoplanin and deltaNp63 protein expression as mandatory predictors, we constructed a 21 genes predictive model of OC. To evaluate the performance of this model, we used a bootstrap method and prediction error curve estimates. Compared to a model that used only the previously described covariates, our predictive model showed a marked improvement in predicting risk of OC, with a prediction error rate of 5%. Conclusions: Gene expression profiles may improve the prediction of OC development in patients with OPL beyond clinical and histological covariates. No significant financial relationships to disclose.
A hepatocyte growth factor antagonist engineered by site-directed mutagenesis.
Authors: F. Cecchi, D. Pajalunga, A. Fowler, D. C. Rabe, B. Peruzzi, N. J. MacDonald, D. K. Blackman, S. j. Stahl, A. Byrd, D. P. Bottaro
Journal: Journal of Clinical Oncology (2011)

10528 Background: Hepatocyte growth factor (HGF) stimulates cell proliferation, motility, and morphogenesis upon binding to the receptor tyrosine kinase Met and cell surface heparan sulfate (HS) glycans. NK1 is a truncated HGF isoform consisting of the N-terminal (N) and first kringle (K1) domains of full-length HGF that stimulates all major HGF biological activities. Within NK1, the N domain contains the HS binding site, while K1 contains the primary determinants of Met binding. Methods: To understand the role of HS in ligand-receptor interaction and biological signaling, we identified three putative HS binding residues in N domain (K60, K62 and R73), generated opposite charge mutations at these positions in NK1, and characterized the recombinantly expressed proteins biochemically and biologically. Results: Nuclear magnetic resonance analysis of mutant and wild type (WT) proteins revealed that no significant structural alterations were introduced by the mutations. The binding of each of the mutant proteins to immobilized heparin was reduced relative to WT, most profoundly in the combined triple mutant (3M). 3M also lacked biological activity, and competitively antagonized HGF activity in normal cells. 3M also potently inhibited oncogenic Met signaling. Soft agar colony formation by HGF-driven tumor cell lines was reduced 50% in the presence of 70 nM 3M protein and abolished in the presence of 300 nM, relative to untreated controls. Similar levels of inhibition were observed using the Met inhibitor PHA665752 at the same concentrations. Ectopic 3M expression in these tumor lines dramatically reduced their growth rate as xenografts in mice and was associated with reduced tumor phosphoMet content. HGF-driven experimental metastasis by B16 cells was blocked by ectopic 3M expression, or by daily intraperitoneal (IP) administration of purified recombinant 3M. Conclusions: Our results show that HS binding is critical for HGF-driven mitogenesis, motogenesis, tumor growth and metastasis, and inhibition of these activities by 3M validates a novel strategy for developing antagonists of the HGF signaling pathway and potentially those of other HS-binding ligands.
Vascular Endothelial Growth Factor (VEGF) Acts Via Auto- and Paracrine Mechanisms as a Critical Microenvironmental Factor for the Survival of Chronic Lymphocytic Leukemia (CLL) Cells.
Authors: Iris Gehrke, Julian Paesler, Rajesh Kumar Gandhirajan, Regina Razavi, Simon Jonas Poll-Wolbeck, Alexandra Filipovich, Sabrina Uhrmacher, Felix Erdfelder, Magdalena Hertweck, Michael Hallek, Karl Anton Kreuzer
Journal: Blood (2009)
Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit
Authors: Tanya Keenan, Thomas W. LeBlanc, Lara Traeger, Harry Vandusen, Gregory A. Abel, David P. Steensma, Amir T. Fathi, Daniel J DeAngelo, Martha Wadleigh, Gabriela Hobbs, Philip C. Amrein, Richard M. Stone, Karen K. Ballen, Yi-Bin Chen, Jennifer S. Temel, Areej El-Jawahri
Journal: Blood (2015)
Pml and TAp73 Interacting at Nuclear Body and Activated p38MAPK Mediate Imatinib-Induced p53-Independent Apoptosis of Chronic Myeloid Leukemia Cells
Authors: Jin-Hwang Liu, Chin-Cheng Liu, Chueh-Chuan Yen, Jyh-Pyng Gau, Cheng-Hwai Tzeng
Journal: Blood (2008)
Feasibility of a Symptom-Adapted Physical Activity Intervention during Induction Chemotherapy for Older Adults with Acute Myeloid Leukemia (AML)
Authors: Heidi D. Klepin, Janet Tooze, Timothy Pardee, Leslie Renee Ellis, Dmitriy Berenzon, Dianna Howard, Wendy Demark-Wahnefried, Shannon Mihalko, William Jack Rejeski, Bayard L. Powell, Stephen Kritchevsky
Journal: Blood (2015)
A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma
Authors: Stephen Spurgeon, Andy I Chen, Craig Okada, Samir Parekh, Violetta V. Leshchenko, Gundula Palmbach, Bashi Ratterree, Nan Subbiah, Christine Capper, Elliot M Epner
Journal: Blood (2011)
Depression and its coping strategies in infertile women undergoing in vitro fertilization and embryo transfer
Authors: WU Geng-xiang, Yang Jing, Yin Tai-lang, XU Wang-ming, Xia Liang-bin
Journal: BMJ (2009)

Objective To know prevalence of depression, its coping strategies and risk factors among infertile women with in vitro fertilization and embryo transfer (IVF-ET) or intracytoplasmic sperm injection. Methods Infertile women with IVF-ET were interviewed with center for epidemiologic studies short depression scale (CES-D10) and an abbreviated version of the COPE inventory (brief COPE), and their basal sex hormone values and estradiol ( E2 ) on the day of human chorionic gonadotropin (HCG) administration were monitored, as well as the number of oocytes yielded was counted. Results Prevalence of depression was 20.6% in infertile women, higher in those with more than eight years of marriage, infertility for more than six years, and receiving treatment for at least three years. Risk of depression among the women of infertility with monthly family income less than 3000 yuan was 14 times as those with more than 3000 yuan and risk of depression among them due to the factors of their husbands was 2/5 as those not due to men's. Depressive symptoms in the women increased with increasing of their basal follicle stimulating hormone (FSH) level, counted egg number and scores of denial items. Occurrence of their depressive symptoms decreased with higher basal E2 levels, and scores of substance use and humor. Conclusions Some infertile women with IVF-ET do have depression and preventive intervention should be aimed at related factors for depression to improve their psychological health.

Key words: 
Fertilization in vitro; Mood disorders; Adaptation, psychological
The Role of Reactive Oxygen Species In Apoptosis Induction of Mantle Cell Lymphoma (MCL); Inhibition of NADPH Oxidase 2 Induces Apoptosis In MCL
Authors: Yuji Miura, Hiroshi Miwa, Toshihito Ohno, Miyako Haneda, Yoshitaka Hosokawa, Masakazu Nitta, Masanori Daibata
Journal: Blood (2010)
Regulatory T cells and type 2 innate lymphoid cell‐dependent asthma
Authors: J. L. Aron, O. Akbari
Journal: Allergy (2017)

Abstract Group 2 innate lymphoid cells ( ILC 2s) are a recently identified group of cells with the potent capability to produce Th2‐type cytokines such as interleukin ( IL )‐5 and IL ‐13. Several studies suggest that ILC 2s play an important role in the development of allergic diseases and asthma. Activation of pulmonary ILC 2s in murine models lacking T and B cells induces eosinophilia and airway hyper‐reactivity ( AHR ), which are cardinal features of asthma. More importantly, numerous recent studies have highlighted the role of ILC 2s in asthma persistence and exacerbation among human subjects, and thus, regulation of pulmonary ILC 2s is a major area of investigation aimed at curbing allergic lung inflammation and exacerbation. Emerging evidence reveals that a group of regulatory T cells, induced Tregs ( iT regs), effectively suppress the production of ILC 2‐driven, pro‐inflammatory cytokines IL ‐5 and IL ‐13. The inhibitory effects of iT regs are blocked by preventing direct cellular contact or by inhibiting the ICOS ‐ ICOS ‐ligand ( ICOSL ) pathway, suggesting that both direct contact and ICOS ‐ ICOSL interaction are important in the regulation of ILC 2 function. Also, cytokines such as IL ‐10 and TGF ‐β1 significantly reduce cytokine secretion by ILC 2s. Altogether, these new findings uncover iT regs as potent regulators of ILC 2 activation and implicate their utility as a therapeutic approach for the treatment of ILC 2‐mediated allergic asthma and respiratory disease.
Retinal biomarkers provide “insight” into cortical pharmacology and disease
Authors: Christine T.O. Nguyen, Flora Hui, Jason Charng, Shajan Velaedan, Anna K. van Koeverden, Jeremiah K.H. Lim, Zheng He, Vickie H.Y. Wong, Algis J. Vingrys, Bang V. Bui, Magnus Ivarsson
Journal: Pharmacology & Therapeutics (2017)
Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials
Authors: Hang Quach, Simon Harrison, Liam J. Fernyhough, Ross Alistair Henderson, Gillian Corbett, Peter Browett, Hilary Anne Blacklock, Craig Underhill, Paul Cannell, Judith Trotman, Emma Link, Linda Cowan, Jack S Li, Meletios A. Dimopoulos, H. Miles Prince
Journal: Blood (2015)
The Protein Tyrosine Phosphatase, Shp2, Positively Contributes to FLT3-ITD-Induced Malignant Disease in Vivo and Co-Localizes with Nuclear Phospho-STAT5 in FLT3-ITD-Expressing Leukemic Cells.
Authors: Sarah C Nabinger, Xing Jun Li, Baskar Ramdas, Yantao He, Xian Zhang, Briana Richine, Joshua Bowling, Seiji Fukuda, Shreevrat Goenka, Ziyue Liu, Gen-Sheng Feng, Menggang Yu, George Sandusky, H. Scott Boswell, Zhong-Yin Zhang, Reuben Kapur, Rebecca J. Chan
Journal: Blood (2012)
Induction of Fetal Hemoglobin by Inactivation of HDAC1 or HDAC2 without Altering Cellular Proliferation
Authors: Erica B. Esrick, Jian Xu, Katherine Lin, Marie Ellen McConkey, Alyse Frisbee, Luke Poveromo, Stuart H. Orkin, James E. Bradner, Benjamin L. Ebert
Journal: Blood (2011)
Pneumocystis Jirovecii Pneumonia (PCP) in Children with Cancer: A Retrospective Cohort Analysis from the Pediatric Health Information System (PHIS) Database, 2004-2009
Authors: Erin M. Guest, Matt Hall, Samir S. Shah, Keith J. August, Joy M. Fulbright, Jennifer L. Goldman, Ram V. Kalpatthi, Mohamed A. Radhi, Alan S. Gamis
Journal: Blood (2014)
Acquired Hemophilia A in an African-American Male After Stem Cell Transplant for Sickle Cell Disease: Successful Treatment with Recombinant Porcine Factor VIII (OBI-1) and Tolerance Induction with Rituximab and Prednisone
Authors: Jay N. Lozier, Khanh Nghiem, Martin Lee, Bonnie Hodsdon, Galen Joe, R. Patrick Weitzel, John F. Tisdale, Matthew Hsieh
Journal: Blood (2012)
Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12
Authors: Tara Baetz, Bingshu E Chen, Stephen Couban, C. Tom Kouroukis, Rena Buckstein, John Kuruvilla, Kang Howson-Jan, David Szwajcer, Massimo Federico, Ralph M. Meyer, Robert Turner, Marina S Djurfeldt, Annette E Hay, Lois Shepherd, Michael Crump
Journal: Blood (2014)
Allogeneic Stem Cell Transplantation for Multiple Myeloma: Possible Role in the Treatment.
Authors: Liisa Volin, Heli Uotinen, Riitta Niittyvuopio, Eeva Juvonen, Anne Nihtinen, Jouni Heiskanen, Vesa Lindstrom, Tapani Ruutu
Journal: Blood (2012)
Mutational Status of Splenic Diffuse Red Pulp Small B-Cell Lymphoma Revealed By Whole Exome Sequencing
Authors: Nerea Martinez, Carmen Almaraz, Manuela Mollejo, Yolanda Campos-Martin, Sophia Derdak, Laura Cereceda, Alexandra Traverse-Glehen, Aurelie Verney, Lucile Baseggio, Fanny Camacho, Jose Pedro Vaque, Sergi Beltran, Ivo Gut, Miguel Angel A. Piris
Journal: Blood (2015)
A smoke-free NHS
Authors: Mary E Black
Journal: BMJ (2017)

It’s time to stop tolerating tobacco smoking on NHS premises

My father, who was a doctor, used to regularly set his trousers on fire. Born in 1924, he started smoking cigarettes as a teenager. He died of a smoking related cancer in 2003. My father tried but failed to stop his tobacco use. As public and medical attitudes to tobacco changed, he reduced his consumption. He almost broke the habit at home and, when caught out, would stuff his still smouldering pipe in his pocket. I perfected my darning skills aged 10 by fixing singed holes in his tweed jacket. His smoking at work was the worst, as there was no ban on smoking and no pressure on him to cut back. …
The Investigational Multi-Targeted Kinase Inhibitor TAK-901 Antagonizes Acute Myeloid Leukemia Pathogenesis: Results of Preclinical Studies
Authors: Patrick Griffin, Steffan T Nawrocki, Takashi Satou, Claudia M Espitia, Kevin R. Kelly, Maki Hasegawa, Swaminathan Padmanabhan, Angela Romanelli, Ron de Jong, Jennifer S Carew
Journal: Blood (2011)